Cargando…

Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept

BACKGROUND: Despite major advances in rheumatoid arthritis outcome, not all patients achieve remission, and there is still an unmet need for new therapeutic approaches. This study aimed at evaluating in a pre-clinical murine model the efficacy of extracorporeal photopheresis (ECP) in the treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Coppard, Céline, Bonnefoy, Francis, Hannani, Dalil, Gabert, Françoise, Manches, Olivier, Plumas, Joel, Perruche, Sylvain, Chaperot, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751641/
https://www.ncbi.nlm.nih.gov/pubmed/31533744
http://dx.doi.org/10.1186/s12967-019-2066-1
_version_ 1783452650106257408
author Coppard, Céline
Bonnefoy, Francis
Hannani, Dalil
Gabert, Françoise
Manches, Olivier
Plumas, Joel
Perruche, Sylvain
Chaperot, Laurence
author_facet Coppard, Céline
Bonnefoy, Francis
Hannani, Dalil
Gabert, Françoise
Manches, Olivier
Plumas, Joel
Perruche, Sylvain
Chaperot, Laurence
author_sort Coppard, Céline
collection PubMed
description BACKGROUND: Despite major advances in rheumatoid arthritis outcome, not all patients achieve remission, and there is still an unmet need for new therapeutic approaches. This study aimed at evaluating in a pre-clinical murine model the efficacy of extracorporeal photopheresis (ECP) in the treatment of rheumatoid arthritis, and to provide a relevant study model for dissecting ECP mechanism of action in autoimmune diseases. METHODS: DBA/1 mice were immunized by subcutaneous injection of bovine collagen type II, in order to initiate the development of collagen-induced arthritis (CIA). Arthritic mice received 3 ECP treatments every other day, with psoralen + UVA-treated (PUVA) spleen cells obtained from arthritic mice. Arthritis score was measured, and immune cell subsets were monitored. RESULTS: ECP-treated mice recovered from arthritis as evidenced by a decreasing arthritic score over time. Significant decrease in the frequency of Th17 cells in the spleen of treated mice was observed. Interestingly, while PUVA-treated spleen cells from healthy mouse had no effect, PUVA-treated arthritic mouse derived-spleen cells were able to induce control of arthritis development. CONCLUSIONS: Our results demonstrate that ECP can control arthritis in CIA-mice, and clarifies ECP mechanisms of action, showing ECP efficacy and Th17 decrease only when arthritogenic T cells are contained within the treated sample. These data represent a pre-clinical proof of concept supporting the use of ECP in the treatment of RA in Human.
format Online
Article
Text
id pubmed-6751641
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67516412019-09-23 Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept Coppard, Céline Bonnefoy, Francis Hannani, Dalil Gabert, Françoise Manches, Olivier Plumas, Joel Perruche, Sylvain Chaperot, Laurence J Transl Med Research BACKGROUND: Despite major advances in rheumatoid arthritis outcome, not all patients achieve remission, and there is still an unmet need for new therapeutic approaches. This study aimed at evaluating in a pre-clinical murine model the efficacy of extracorporeal photopheresis (ECP) in the treatment of rheumatoid arthritis, and to provide a relevant study model for dissecting ECP mechanism of action in autoimmune diseases. METHODS: DBA/1 mice were immunized by subcutaneous injection of bovine collagen type II, in order to initiate the development of collagen-induced arthritis (CIA). Arthritic mice received 3 ECP treatments every other day, with psoralen + UVA-treated (PUVA) spleen cells obtained from arthritic mice. Arthritis score was measured, and immune cell subsets were monitored. RESULTS: ECP-treated mice recovered from arthritis as evidenced by a decreasing arthritic score over time. Significant decrease in the frequency of Th17 cells in the spleen of treated mice was observed. Interestingly, while PUVA-treated spleen cells from healthy mouse had no effect, PUVA-treated arthritic mouse derived-spleen cells were able to induce control of arthritis development. CONCLUSIONS: Our results demonstrate that ECP can control arthritis in CIA-mice, and clarifies ECP mechanisms of action, showing ECP efficacy and Th17 decrease only when arthritogenic T cells are contained within the treated sample. These data represent a pre-clinical proof of concept supporting the use of ECP in the treatment of RA in Human. BioMed Central 2019-09-18 /pmc/articles/PMC6751641/ /pubmed/31533744 http://dx.doi.org/10.1186/s12967-019-2066-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Coppard, Céline
Bonnefoy, Francis
Hannani, Dalil
Gabert, Françoise
Manches, Olivier
Plumas, Joel
Perruche, Sylvain
Chaperot, Laurence
Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept
title Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept
title_full Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept
title_fullStr Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept
title_full_unstemmed Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept
title_short Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept
title_sort photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751641/
https://www.ncbi.nlm.nih.gov/pubmed/31533744
http://dx.doi.org/10.1186/s12967-019-2066-1
work_keys_str_mv AT coppardceline photopheresisefficacyinthetreatmentofrheumatoidarthritisapreclinicalproofofconcept
AT bonnefoyfrancis photopheresisefficacyinthetreatmentofrheumatoidarthritisapreclinicalproofofconcept
AT hannanidalil photopheresisefficacyinthetreatmentofrheumatoidarthritisapreclinicalproofofconcept
AT gabertfrancoise photopheresisefficacyinthetreatmentofrheumatoidarthritisapreclinicalproofofconcept
AT manchesolivier photopheresisefficacyinthetreatmentofrheumatoidarthritisapreclinicalproofofconcept
AT plumasjoel photopheresisefficacyinthetreatmentofrheumatoidarthritisapreclinicalproofofconcept
AT perruchesylvain photopheresisefficacyinthetreatmentofrheumatoidarthritisapreclinicalproofofconcept
AT chaperotlaurence photopheresisefficacyinthetreatmentofrheumatoidarthritisapreclinicalproofofconcept